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Research ArticleMirtoselect, an anthocyanin-rich bilberry extract,
attenuates non-alcoholic steatohepatitis and associated
ﬁbrosis in ApoE⁄3Leiden mice
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(EA11), 9713 GZ Groningen, The Netherlands; 3Top Institute Food and Nutrition, Nieuwe Kanaal 9A, 6709 PA Wageningen, The NetherlandsBackground & Aims: Anthocyanins may have beneﬁcial effects
on lipid metabolism and inﬂammation and are demonstrated to
have hepatoprotective properties in models of restraint-stress-
and chemically-induced liver damage. However, their potential
to protect against non-alcoholic steatohepatitis (NASH) under
conditions relevant for human pathogenesis remains unclear.
Therefore, we studied the effects of the standardised antho-
cyanin-rich extract Mirtoselect on diet-induced NASH in a
translational model of disease.
Methods: ApoE⁄3Leiden mice were fed a Western-type
cholesterol-containing diet without (HC) or with 0.1% (w/w)
Mirtoselect (HCM) for 20 weeks to study the effects on diet-in-
duced NASH.
Results:Mirtoselect attenuated HC-induced hepatic steatosis, as
observed by decreased macro- and microvesicular hepatocellular
lipid accumulation and reduced hepatic cholesteryl ester content.
This anti-steatotic effect was accompanied by local anti-
inﬂammatory effects in liver, as demonstrated by reduced inﬂam-
matory cell clusters and reduced neutrophil inﬁltration in HCM.
On a molecular level, HC diet signiﬁcantly induced hepatic
expression of pro-inﬂammatory genes Tnf, Emr1, Ccl2, Mpo,
Cxcl1, and Cxcl2 while this induction was less pronounced or sig-
niﬁcantly decreased in HCM. A similar quenching effect was
observed for HC-induced pro-ﬁbrotic genes, Acta2 and Col1a1
and this anti-ﬁbrotic effect of Mirtoselect was conﬁrmed
histologically. Many of the pro-inﬂammatory and pro-ﬁbrotic
parameters positively correlated with intrahepatic free choles-
terol levels. Mirtoselect signiﬁcantly reduced accumulation and
crystallisation of intrahepatic free cholesterol, providing a possi-
ble mechanism for the observed hepatoprotective effects.Journal of Hepatology 20
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Non-alcoholic fatty liver disease (NAFLD) is the most common
cause of chronic liver disease in Western countries [1,2]. It consti-
tutes a spectrum of liver injury, ranging from the clinically benign
intrahepatic accumulation of lipids (steatosis), to the more
progressive non-alcoholic steatohepatitis (NASH). In addition to
hepatic lipid accumulation, NASH is characterised by hepatic
inﬂammation, i.e. inﬁltration of immune cells [3] and can further
progress to ﬁbrosis, cirrhosis and hepatocellular carcinoma.
Although the mechanisms by which NASH progresses are not
completely understood, it is thought that dysregulation of choles-
terol homeostasis and subsequent accumulation of free (unesteri-
ﬁed) cholesterol are linked to the pathogenesis of NASH in
humans (reviewed in reference [4]). In line with this notion,
emerging experimental evidence implicates free cholesterol as a
potential trigger of inﬂammation [5] as well as a possible driving
factor in the development of ﬁbrosis [6,7]. A recent study in
experimental and human NASH revealed that intrahepatic
accumulation of free cholesterol can lead to the formation of
cholesterol crystals in hepatocyte lipid droplets, which may form
an important trigger for the progression of simple steatosis to
NASH [8].
The anthocyanins, a subclass of the polyphenols, comprise a
large group of bioactive compounds that are considered to have
many health-promoting effects [9], including cholesterol-
lowering [10,11] and anti-inﬂammatory effects [12] which may
mediate potential hepatoprotective properties [13]. Here we
studied the effects of the standardised anthocyanin-rich bilberry
(Vaccinium myrtillus L.) extract Mirtoselect on the development of15 vol. 62 j 1180–1186
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NASH. This extract has been demonstrated to reduce circulating
makers of inﬂammation in humans [14,15] and has beneﬁcial
effects in restraint-stress- [16,17] and chemically-induced [18]
models of liver damage. However, its hepatoprotective potential
in diet-induced metabolic inﬂammation and liver disease is
unclear. Therefore we studied effects of Mirtoselect on NASH in
ApoE⁄3Leiden (E3L) mice, a translational model of disease [19].
These mice develop diet-induced dyslipidaemia and inﬂamma-
tion on a high-fat/high-cholesterol diet [20], and ultimately
develop NASH with ﬁbrosis. Earlier studies have shown that
E3L mice are sensitive to nutritional [21] and pharmacological
[19] interventions, and show human-like responses to hypolipi-
daemic compounds [19,22].
Combined histological, biochemical, and gene expression
analyses revealed that Mirtoselect reduces development of
NASH, attenuating both steatosis and inﬂammation as well as
the development of hepatic ﬁbrosis. These effects were associated
with a reduction in hepatic free cholesterol accumulation and
cholesterol crystal formation.HC HCM REF F 
Fig. 1. Mirtoselect attenuates hepatic steatosis in cholesterol-fed E3L mice.
(A) Representative photomicrographs of liver sections of reference (REF), high-
cholesterol control (HC) and Mirtoselect-treated mice (HCM). Mirtoselect
attenuated HC diet-induced macrovesicular (B) and microvesicular (C) steatosis.
(D) Hepatic steatosis in HC mice was mainly attributable to accumulation of
cholesteryl esters, the build-up of which was decreased by Mirtoselect. (E)
Hepatic triglycerides tended to accumulate in HC, which was not observed in
HCM. (F) In HC-fed animals, some hypertrophic cells were CK18-deﬁcient
compared with neighbouring cells (arrows); presence of these cells was reduced
in HCM. REF: non-cholesterol-fed reference, HC: high-cholesterol control, HCM:
high-cholesterol + Mirtoselect. Data are mean ± SD. ⁄p <0.05, ⁄⁄p <0.01,
⁄⁄⁄p <0.001 compared with HC.Materials and methods
Animal experiments
Experiments were approved by an independent Animal Care and Use Committee
and were in compliance with European Community speciﬁcations regarding the
use of laboratory animals. E3L mice were used because they allow for the study
of diets and nutrients on lipids (including cholesterol) and liver inﬂammation
[19,23,24].
Female E3L mice were fed a Western-type diet (15% cocoa butter, 1% corn oil,
40.5% sucrose, 20% acid casein, 10% corn starch and 6.2% cellulose; diet-T; AB-
Diets, Woerden, The Netherlands), supplemented with 1% (w/w) cholesterol
(Sigma-Aldrich, Zwijndrecht, The Netherlands) for 20 weeks. The study included
a 4-week run-in during which all mice received this diet, after which they were
matched for plasma cholesterol and triglycerides into three experimental groups
(n = 15/group). Control animals (HC) continued to receive the Western-type diet
for the remainder of the study, while Mirtoselect-treated animals (HCM) received
the HC diet with addition of 0.1% (w/w) Mirtoselect (Indena S.A.S., Paris, France).
This standardised bilberry (Vaccinium myrtillus L.) extract contains 36% antho-
cyanins. An ageing reference group (REF) received the same Western-type diet
mentioned above, but without cholesterol supplementation. Food intake and
body weight were monitored throughout the study. Every 4 weeks, blood samples
were collected via tail vein bleeding after a 4 h fast for isolation of EDTA plasma.
Animals were sacriﬁced by CO2 asphyxiation after 16 weeks of dietary treatment
to collect livers. The medial lobe was ﬁxed in formalin and embedded in parafﬁn
for histological analysis of NASH and the left lobe was snap frozen in liquid nitro-
gen and stored at 80 C for cryosectioning, liver lipid- and mRNA-expression
analyses.
Histological, biochemical and hepatic gene expression analyses
A detailed description of (immuno)histological, biochemical, and gene expression
analyses is provided in (Supplementary Material and methods). Brieﬂy, develop-
ment of NASH was assessed histologically using an adapted grading method for
human NASH [25,26]. Plasma lipids were determined with commercially avail-
able enzymatic assays and liver lipids were analysed by HPTLC, as described
previously [27]. Hepatic gene expression analyses were performed by RT-PCR,
using TaqMan Gene Expression Assays (Life Technologies, Bleiswijk, The
Netherlands) and changes in gene expression were calculated using the compara-
tive Ct (DDCt) method, expressed as fold-change relative to REF. Illumina
microarray analysis of hepatic gene expression was performed following estab-
lished normalisation and quality control protocols followed by gene enrichment
analysis across pathways and biological processes as described [23]. p65-NFjB
activity was determined in liver homogenates by DNA-binding ELISA
(TransAM p65-NFjB Chemi Kit, Active Motif, La Hulpe, Belgium) according to
manufacturer’s instructions and as described [26].Journal of Hepatology 2015Statistical analyses
All data are presented as mean ± SD. Statistical analyses were performed using
SPSS software (version 22, IBM, Armonk, USA). For normally distributed variables,
signiﬁcance of differences between groups was tested by one-way ANOVA, with
Dunnett’s multiple comparison post-hoc test to compare HC vs. REF and HC vs.
HCM. In case of heterogeneity between groups, variables were analysed by
ANOVA using Brown-Forsythe for differences between groups with Dunnett’s
T3 post-hoc test. Non-normally distributed variables were tested by non-
parametric Kruskal-Wallis test followed by Mann-Whitney U. A p value <0.05
was considered statistically signiﬁcant.Results
Mirtoselect attenuates hepatic steatosis and hepatocellular damage
Treatments were well tolerated and there was no effect of
Mirtoselect on food intake or body weight (Supplementary
Fig. 2A–B). HC-feeding induced hepatosteatosis relative to REF,
as observed histologically by a non-zonal accumulation of lipid
macrovesicles and microvesicles in hepatocytes (Fig. 1A).vol. 62 j 1180–1186 1181
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Fig. 2. Mirtoselect reduces hepatic inﬂammation in cholesterol-fed E3L mice.
(A) Number of HC-induced inﬂammatory cell aggregates was reduced by
Mirtoselect. HC diet induced Emr1 (B) and Ccl2 (C) gene expression was not
affected by Mirtoselect. Mirtoselect reduced HC-inducedMpo gene expression (D)
and number of MPO-positive cells as determined immunohistochemically (E).
HC-induced gene expression of neutrophil chemoattractants Cxcl1 (F) and Cxcl2
(G) was less pronounced in HCM. REF: non-cholesterol-fed reference, HC: high-
cholesterol control, HCM: high-cholesterol + Mirtoselect. Data are mean ± SD.
⁄p <0.05, ⁄⁄p <0.01, ⁄⁄⁄p <0.001 compared with HC.
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ig. 3. Development of hepatic ﬁbrosis in cholesterol-fed E3L mice reduced by
irtoselect. (A) Representative photomicrographs of picro-sirius red-stained
ver sections show reduction of HC-induced collagen content in Mirtoselect-
eated mice, which was conﬁrmed by biochemical analysis of hepatic collagen
ontent (B). (C) Induction of Col1a1 gene expression is prevented by Mirtoselect.
ene expression of hepatic stellate cell activation marker Acta2 (D) as well as pro-
brotic cytokines Tgfb1 (E) and Tnf (F) was induced by HC, while this induction
as less pronounced in HCM. REF: non-cholesterol-fed reference, HC: high-
holesterol control, HCM: high-cholesterol + Mirtoselect. Data are mean ± SD.
<0.05, ⁄⁄p <0.01, ⁄⁄⁄p <0.001 compared with HC.
Research ArticleMirtoselect attenuated the development of hepatic steatosis
(Fig. 1A), completely preventing the HC-induced increase in
macrovesicular steatosis (p <0.001, Fig. 1B) and strongly decreas-
ing microvesicular steatosis (p = 0.027, Fig. 1C). Analysis of intra-
hepatic lipid composition revealed that this increase in hepatic
steatosis in HC was mainly attributable to an accumulation of
lipids esteriﬁed to cholesterol (cholesteryl esters), the concentra-
tion of which was signiﬁcantly lower in HCM (p = 0.008, Fig. 1D).
Comparably, hepatic triglyceride levels (i.e. lipids esteriﬁed to
glycerol) tended to build-up in HC, but no increase was observed
in HCM (Fig. 1E). In association with steatosis, HC-feeding
resulted in a pronounced induction of hepatocellular hypertro-
phy, the development of which was markedly reduced in HCM
(p = 0.034, Supplementary Fig. 3). In HC-fed animals, some of
these hypertrophic cells were deﬁcient in cytokeratin 18 (CK
18) compared with neighbouring cells (Fig. 1F), indicating loss
of cytoskeletal function and hepatocellular damage as seen in
ballooning cells in human NASH [28,29]. In Mirtoselect-treated
mice, only very few enlarged CK-18 deﬁcient cells were observed
(Fig. 1F), indicating a reduction in hepatocellular damage.
Mirtoselect reduces hepatic inﬂammation
In addition to hepatosteatosis, a deﬁning characteristic of NASH
is the presence of hepatic inﬂammation, which can be observed
histologically as the lobular inﬁltration of inﬂammatory cells,
i.e. inﬂammatory aggregates containing mononuclear cells1182 Journal of Hepatology 2015F
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⁄p(F4/80-positive cells of the monocyte/macrophage lineage) and
polymorph nuclear cells (MPO-positive granulocytes, i.e. neu-
trophils). In comparison with REF, the number of inﬂammatory
cell aggregates increased strongly in HC, and this HC-induced
hepatic inﬂammatory response was fully attenuated with
Mirtoselect (p <0.001, Fig. 2A). Investigation of hepatic Emr1
(F4/80) gene expression revealed that the inﬂux of inﬂammatory
cells was partly attributable to macrophages, which was
supported by increased gene expression levels of Ccl2 (MCP-1),
a mediator of monocyte recruitment (Fig. 2B–C). Mirtoselect did
not affect expression of Emr1 or Ccl2 (Fig. 2B–C), indicating that
its anti-inﬂammatory effect may impair the inﬂux of another
immune cell type. Hepatic gene expression analysis of the neu-
trophil marker Mpo showed that Mpo expression was increased
in HC animals and this induction was completely prevented in
HCM animals (p = 0.034, Fig. 2D). Immunohistochemical staining
of MPO-positive cells conﬁrmed the mRNA expression data and
showed that HC induced neutrophil inﬁltration, which was
attenuated by HCM (Fig. 2E). In line with these ﬁndings, the
expression of two neutrophil chemoattractants – Cxcl1 and
Cxcl2 – was upregulated strongly and signiﬁcantly by HC-feeding
while induction of these chemokines were less pronounced in
HCM animals (Cxcl1: p = 0.327, Cxcl2: p = 0.131, Fig. 2F–G).
Mirtoselect attenuates hepatic ﬁbrosis
Continued hepatic inﬂammation is thought to drive the progres-
sion of NASH, ultimately resulting in the development of hepatic
ﬁbrosis. Histochemical staining of hepatic collagen content by
picro-sirius red staining demonstrated that the HC diet causedvol. 62 j 1180–1186
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Fig. 4. Mirtoselect reduces intrahepatic free cholesterol accumulation and
crystallisation in cholesterol-fed E3L mice. (A) Intrahepatic free cholesterol
levels correlated with hepatic inﬂammation (inﬂammatory aggregates per ﬁeld)
and (B) hepatic ﬁbrosis (Col1a1 expression). (C) HC-induced hepatic free
cholesterol accumulation was not observed in HCM. (D) Representative pho-
tomicrographs of liver cryosections (same ﬁeld under bright-ﬁeld and polarised-
light microscopy) reveal presence of birefringent crystals in HC that were hardly
observed in HCM. (E) Quantiﬁcation of birefringent area shows strong HC-
induced increase that is not observed in HCM. (F) Birefringent crystals stained
prominently with free cholesterol staining ﬁlipin (same ﬁeld under polarised-
light and ﬂuorescent microscopy). REF: non-cholesterol-fed reference, HC: high-
cholesterol control, HCM: high-cholesterol + Mirtoselect. Data are mean ± SD.
⁄⁄p <0.01 compared with HC.
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liver ﬁbrosis, characterised by periportal, pericentral and peris-
inusoidal deposition of collagen. This HC-induced ﬁbrosis was
much less pronounced in HCM (Fig. 3A). In line with these
histological observations, biochemical analysis of hepatic col-
lagen content revealed a pronounced increase in collagen content
in HC compared with REF, which was signiﬁcantly reduced in
HCM (p = 0.034, Fig. 3B) and hepatic gene expression analysis of
Col1a1 showed signiﬁcantly increased expression in HC
compared with REF, while Mirtoselect quenched this effect and
signiﬁcantly reduced Col1a1 expression compared with HC
(p = 0.011, Fig. 3C). Additionally, HC diet signiﬁcantly induced
expression of the hepatic stellate cell activation marker Acta2
(a-SMA) (Fig. 3D), as well as the pro-ﬁbrotic cytokines Tgfb1
(TGF-b) and Tnf (TNF-a) (Fig. 3E–F). In line with the attenuating
effect of Mirtoselect on hepatic ﬁbrosis development, the induc-
tion of these genes was less pronounced, although not signiﬁ-
cantly, in HCM (Acta2: p = 0.173, Tgfb1: p = 0.174, Tnf: p = 0.096,
Fig. 3D–F). Subsequent microarray pathway analysis revealed
that many genes downstream of TGF-b were affected, indicating
strongly and signiﬁcantly activated TGF-b signalling in HC com-
pared with REF (z = 7.539, p = 2.5E-51). Mirtoselect strongly
inhibited activation of this pathway (z = 4.862, p = 3.3E-20
compared with HC). Consistent with this, the process ‘Hepatic
ﬁbrosis/hepatic stellate cell activation’, was strongly activated
in HC compared with REF, and Mirtoselect suppressed this activa-
tion (Supplementary Fig. 4). Together, our data demonstrate that
HC-feeding induced histopathological and molecular hallmarks of
NASH and ﬁbrosis and that Mirtoselect signiﬁcantly attenuated
disease development.
Intrahepatic free cholesterol correlates with development of NASH
and is reduced by Mirtoselect
To gain more insight into the metabolic-inﬂammatory processes
that drive the development of NASH and hepatic ﬁbrosis and the
effects of Mirtoselect thereupon, we next analysed a possible
metabolic trigger of inﬂammation: cholesterol. HC-feeding
induced dyslipidaemia with increased plasma total cholesterol
compared with REF, speciﬁcally in the VLDL- and LDL-sized
particles. Mirtoselect did not affect circulating cholesterol levels
or lipoprotein proﬁle (Supplementary Fig. 5) pointing to a hepato-
protective effect within the liver tissue. As intrahepatic free
cholesterol is a very potent inducer of liver inﬂammation [23]
and is elevated intrahepatically in humanNASH [30,31], we deter-
mined free cholesterol concentrations in freshly prepared liver
homogenates and correlated themwith histology scores and gene
expression data. Both hepatic inﬂammation (number of inﬂam-
matory clusters observed histologically, p <0.001), and hepatic
ﬁbrosis (hepatic Col1a1 expression, p = 0.007) were positively cor-
related with hepatic free cholesterol levels (Fig. 4A–B). Further
strengthening this notion, we also observed positive signiﬁcant
correlations of hepatic free cholesterol levels with the expression
level of many of the investigated pro-inﬂammatory and pro-ﬁbro-
tic parameters (i.e. Ccl2, Cxcl1, Cxcl2, Acta2, Tgfb1, and Tnf, shown
in Supplementary Fig. 6). Importantly, Mirtoselect fully blunted
the disease-associated increase in hepatic free cholesterol, the
concentrations of which were comparable to REF and signiﬁcantly
lower than in HC (p = 0.008, Fig. 4C). To further examine the link
between cholesterol and inﬂammation and the effects of
Mirtoselect thereupon we analysed activation of inﬂammatory
pathways by microarray as well as biochemically. HC dietJournal of Hepatology 2015signiﬁcantly induced TNF-a and IL-1b signalling (TNF-a:
z = 7.539, p = 2.5E-51; IL-1b: z = 6.516, p = 4.70E-30; vs. REF) and
activated the downstream pro-inﬂammatory transcription factor
NFjB (z = 6.245, p4.82E-14 vs. REF). Consistent with this, hepatic
free cholesterol levels were positively correlated with biochemi-
cally measured transcriptional activation of p65-NFjB
(R2 = 0.51, p = 0.021), providing a link between cholesterol and
inﬂammation. Mirtoselect signiﬁcantly reduced p65-NFjB activ-
ity relative to HC (fold-change relative to REF: 1.15 ± 0.11 in HC
vs. 0.98 ± 0.05 in HCM, p = 0.032).
More detailed analysis of processes that may underlie
observed effects of Mirtoselect on hepatic cholesterol accumula-
tion showed that plasma markers of cholesterol uptake (plant
sterols to cholesterol ratio and cholestanol to cholesterol ratio)
or cholesterol biosynthesis (lathosterol to cholesterol ratio) were
not affected in HCM (Supplementary Fig. 7). Also, microarray
analysis conﬁrmed the absence of an effect of Mirtoselect on
cholesterol biosynthesis but revealed a signiﬁcant activation of
FXR in HCM (z = 2.190, p = 7.64E-03) and showed that genes
involved in bile acid synthesis, bile acid conjugation and bile salt
secretion (e.g. Bsep, Cyp27a1) were upregulated in HCM.
Reﬁned microscopic analysis of liver cross-sections under
polarised light revealed that HC-feeding caused pronounced
formation of large birefringent crystals within a considerable
amount of the macrovesicular lipid droplets, while these crystals
were hardly observed in Mirtoselect-treated animals (even in thevol. 62 j 1180–1186 1183
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few regions containing macrovesicles, Fig. 4D–E). These birefrin-
gent crystals stained positively with ﬁlipin (Fig. 4F), which forms
a ﬂuorescent complex with free cholesterol speciﬁcally, indicat-
ing that the observed birefringence is attributable to crystallised
free cholesterol. Detailed examination of the liver cross-sections
under bright-ﬁeld and polarised-light microscopy revealed that
many of the hepatocytes containing these crystals were devoid
of normal cellular morphology and organisation. The prevention
of this intrahepatic cholesterol crystal formation by Mirtoselect
provides a possible rationale for its observed hepatoprotective
properties.Discussion
We investigated the potential hepatoprotective properties of a
standardised anthocyanin-rich extract (Mirtoselect) in a diet-
induced, translational model of NASH with ﬁbrosis. We show that
Mirtoselect protects against the development of NASH, reducing
hepatic steatosis, hepatic inﬂammation and hepatic ﬁbrosis,
associated with decreased accumulation and crystallisation of
intrahepatic free cholesterol. The observed hepatoprotective
effects of Mirtoselect were achieved at a dosage that translates
to an anthocyanin intake of around 300 mg/day in humans, an
intake that is achievable by diet [12,32,33].
HC diet-feeding induced intrahepatic lipid accumulation char-
acterised by macro- and microvesicular steatosis, which was
mainly attributable to an increase in lipids esteriﬁed to choles-
terol. Mirtoselect strongly reduced this intrahepatic accumulation
of lipids. Experimental support for these observed anti-steatotic
effects is provided by results from earlier studies that report
improved hepatic cholesterol homeostasis in rodents treated with
similar concentrations of anthocyanin-rich extracts [11,34] or
individual anthocyanins [35]. Although these studies were not
performed under conditions leading to NAFLD/NASH, they do
provide a possible mechanism for the observed reduction in intra-
hepatic cholesterol: intervention with anthocyanins was found to
increase bile acid synthesis [34,35] and faecal sterol excretion
[11,35], thereby decreasing intrahepatic cholesterol accumulation
[11,35] which is consistent with our observations of FXR activa-
tion by Mirtoselect. Although it is the anthocyanin fraction of
Mirtoselect that is considered to be the principal bioactive frac-
tion of the extract, it is unknown which of these anthocyanins
or other possibly bioactive constituents (alone or in combination),
may be responsible for the observed effects.
In addition to reducing hepatic steatosis Mirtoselect also
attenuated hepatic inﬂammation, completely preventing the
HC-induced increase in inﬂammatory cell aggregates. This
anti-inﬂammatory effect was largely attributable to an effect
speciﬁcally on the inﬂux of MPO-positive neutrophils, the inﬁl-
tration of which is recognised as a deﬁning characteristic of
inﬂammation in human NASH [36]. The exact role of neutrophils
in the pathogenesis of NASH remains to be elucidated [37], but
their ability to release a potent cocktail of reactive oxygen species
and proteases implicates them as a potential cause of extensive
tissue damage [38] that may contribute to ampliﬁcation of the
inﬂammatory response as well as development of ﬁbrosis. We
observed a marked reduction of neutrophils in livers of
Mirtoselect-treated mice, but only a modest effect on the hepatic
expression of neutrophil chemoattractants Cxcl1 and Cxcl2, sug-
gesting additional mechanisms outside the liver. Indeed, it has1184 Journal of Hepatology 2015been demonstrated that anthocyanins can attenuate the induc-
tion of chemokine receptors such as CXCR2 [39], which is
required for neutrophil chemotaxis.
Although inﬂammation is recognised to play an important
role in the development of NASH, the nature of the trigger for this
inﬂammatory component remains unclear. Lipotoxicity caused
by the build-up of toxic lipid species is thought to play an
important role, but the speciﬁc lipid species that mediate hepatic
lipotoxicity have not been speciﬁcally identiﬁed [40]. While
triglycerides are the main accumulating lipid species in human
NASH, recent studies have implicated free cholesterol as a poten-
tial trigger for disease progression [4]. The experimental condi-
tions chosen for the present study emphasize the role of
cholesterol in NASH, and limit the study of hepatic triglyceride
accumulation. Results from epidemiological studies that link
dietary cholesterol intake to increased risk and severity of
NAFLD [41,42] and cirrhosis [43] provide indications that choles-
terol may play a causal role in NASH development. In support of
this notion, free cholesterol is increased intrahepatically in
human [30,31] and experimental NASH [44], and modulation of
hepatic free cholesterol levels by diet [44] or pharmacological
intervention [45] is closely linked to the severity of experimental
NASH. Furthermore, there are indications that cholesterol-lower-
ing agents (e.g. statins, ezetimibe) may improve NASH in patients
with hypercholesterolaemia [46,47]. Mechanistic studies have
shown that free cholesterol accumulation in Kupffer cells [48]
and hepatic stellate cells (HSC) [6,7] promotes inﬂammation
and exacerbates ﬁbrosis (e.g. increased TNF-a and CCL2 expres-
sion by Kupffer cells and increased COL1A1 expression in HSC).
Results from the study described herein show that intrahepatic
free cholesterol levels are positively correlated with many factors
that contribute to or reﬂect progressive development of NASH
(e.g. Ccl2, Cxcl1, Cxcl2, Col1a1, Acta2, Tnf, and Tgfb1). The observed
activation of inﬂammatory signalling routes (IL-1b, TNF-a, TGF-b)
by HC as well as the positive correlation between free cholesterol
and NF-jB activity, point to NF-jB activation as an effector of
cholesterol-induced inﬂammation, which is in line with previous
observations [23,27]. Mirtoselect decreases the build-up of this
cytotoxic lipid species and associated NF-jB activation, thereby
providing a possible explanation for its beneﬁcial effects on
NAFLD development.
A recently emerging mechanism of cellular toxicity associated
with free cholesterol accumulation is intracellular cholesterol
crystallisation, which can happen when the concentration of free
cholesterol reaches a very high level [49]. Cholesterol crystals,
particularly when they are very small (nm range), can trigger
inﬂammation through inﬂammasome activation [5,50]. Besides
putative pro-inﬂammatory effects of cholesterol crystals [5,50],
it is plausible that the sheer size of the intrahepatocellular
cholesterol crystals observed in the present study (with diame-
ters ranging up to 50 lm) would also cause extensive physical
damage to the cells consisting of them. Indeed, the formed
cholesterol crystals may damage cells by physically disrupting
the integrity of intracellular structures [49], in line with observa-
tions in the present study. Furthermore, cellular damage can
result in the release of damage associated molecular patterns,
which lead to neutrophil recruitment [37] further enhancing
the inﬂammatory response. Additional support for this mecha-
nism is provided by results from human studies showing that
cholesterol crystals distinguish NASH from simple steatosis [8]
and that this accumulation and crystallisation of free cholesterolvol. 62 j 1180–1186
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within steatotic hepatocytes may be an important trigger for
disease progression.
Overall, we show that Mirtoselect has beneﬁcial effects in
NASH, improving hepatic steatosis, inﬂammation and ﬁbrosis.
Furthermore, we demonstrate the presence of cholesterol crystals
and associated tissue damage in NASH and show that dietary
intervention with Mirtoselect prevents this accumulation and
crystallisation of free cholesterol, providing a possible rationale
for its hepatoprotective effects. Given the moderate dose of
Mirtoselect used, this study suggests that intervention with natu-
rally occurring, well tolerated polyphenols may constitute a
powerful approach to delay NASH development.Financial support
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